286 related articles for article (PubMed ID: 9678800)
21. Relevance of proteins C and S, antithrombin III, von Willebrand factor, and factor VIII for the development of hepatic veno-occlusive disease in patients undergoing allogeneic bone marrow transplantation: a prospective study.
Lee JH; Lee KH; Kim S; Lee JS; Kim WK; Park CJ; Chi HS; Kim SH
Bone Marrow Transplant; 1998 Nov; 22(9):883-8. PubMed ID: 9827816
[TBL] [Abstract][Full Text] [Related]
22. The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia.
Byrne JL; Stainer C; Cull G; Haynes AP; Bessell EM; Hale G; Waldmann H; Russell NH
Bone Marrow Transplant; 2000 Feb; 25(4):411-7. PubMed ID: 10723585
[TBL] [Abstract][Full Text] [Related]
23. TNF alpha levels are increased during bone marrow transplantation conditioning in patients who develop acute GVHD.
Remberger M; Ringden O; Markling L
Bone Marrow Transplant; 1995 Jan; 15(1):99-104. PubMed ID: 7742764
[TBL] [Abstract][Full Text] [Related]
24. A comparison of related donor peripheral blood and bone marrow transplants: importance of late-onset chronic graft-versus-host disease and infections.
Anderson D; DeFor T; Burns L; McGlave P; Miller J; Wagner J; Weisdorf D
Biol Blood Marrow Transplant; 2003 Jan; 9(1):52-9. PubMed ID: 12533742
[TBL] [Abstract][Full Text] [Related]
25. High interleukin-10 serum levels are associated with fatal outcome in patients after bone marrow transplantation.
Hempel L; Körholz D; Nussbaum P; Bönig H; Burdach S; Zintl F
Bone Marrow Transplant; 1997 Sep; 20(5):365-8. PubMed ID: 9339750
[TBL] [Abstract][Full Text] [Related]
26. Risk-adjusted monitoring of veno-occlusive disease following Bayesian individualization of busulfan dosage for bone marrow transplantation in paediatrics.
Brice K; Valerie B; Claire G; Valerie M; Yves B; Gilles A; Nathalie B
Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):135-43. PubMed ID: 17952879
[TBL] [Abstract][Full Text] [Related]
27. Risk factors for hepatic veno-occlusive disease after bone marrow transplantation: retrospective analysis of 137 cases at a single institution.
Kami M; Mori S; Tanikawa S; Akiyama H; Onozawa Y; Tanaka T; Okamoto R; Maeda Y; Sasaki T; Kaku H; Matsuura Y; Hiruma K; Sakamaki H
Bone Marrow Transplant; 1997 Sep; 20(5):397-402. PubMed ID: 9339756
[TBL] [Abstract][Full Text] [Related]
28. Bone marrow transplantation in children: consequences for renal function shortly after and 1 year post-BMT.
Kist-van Holthe JE; van Zwet JM; Brand R; van Weel MH; Vossen JM; van der Heijden AJ
Bone Marrow Transplant; 1998 Sep; 22(6):559-64. PubMed ID: 9758343
[TBL] [Abstract][Full Text] [Related]
29. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome.
Safdar A; van Rhee F; Henslee-Downey JP; Singhal S; Mehta J
Bone Marrow Transplant; 2001 Nov; 28(9):873-8. PubMed ID: 11781648
[TBL] [Abstract][Full Text] [Related]
30. Endothelial cell markers in bone marrow transplant recipients with and without acute graft-versus-host disease.
Salat C; Holler E; Kolb HJ; Pihusch R; Reinhardt B; Hiller E
Bone Marrow Transplant; 1997 May; 19(9):909-14. PubMed ID: 9156265
[TBL] [Abstract][Full Text] [Related]
31. Changes in protein C, factor VII and endothelial markers after autologous bone marrow transplantation: possible implications in the pathogenesis of veno-occlusive disease.
Bazarbachi A; Scrobohaci ML; Gisselbrecht C; Marolleau JP; Mansi A; Brice P; Gorra P; Drouet L
Nouv Rev Fr Hematol (1978); 1993 Apr; 35(2):135-40. PubMed ID: 8332449
[TBL] [Abstract][Full Text] [Related]
32. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
33. Bloodstream infections can develop late (after day 100) and/or in the absence of neutropenia in children receiving allogeneic bone marrow transplantation.
Romano V; Castagnola E; Dallorso S; Lanino E; Calvi A; Silvestro S; Morreale G; Giacchino R; Dini G
Bone Marrow Transplant; 1999 Feb; 23(3):271-5. PubMed ID: 10084259
[TBL] [Abstract][Full Text] [Related]
34. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
[TBL] [Abstract][Full Text] [Related]
35. Early elevation of C-reactive protein correlates with severe infection and nonrelapse mortality in children undergoing allogeneic stem cell transplantation.
McNeer JL; Kletzel M; Rademaker A; Alford K; O'Day K; Schaefer C; Duerst R; Jacobsohn DA
Biol Blood Marrow Transplant; 2010 Mar; 16(3):350-7. PubMed ID: 20005964
[TBL] [Abstract][Full Text] [Related]
36. Laboratory markers of veno-occlusive disease in the course of bone marrow and subsequent liver transplantation.
Salat C; Holler E; Wolf C; Kolb HJ; Reinhardt B; Pihusch R; Krämling HJ; Heinemann V; Haller M; Hiller E
Bone Marrow Transplant; 1997 Mar; 19(5):487-90. PubMed ID: 9052916
[TBL] [Abstract][Full Text] [Related]
37. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Ringdén O; Labopin M; Gorin NC; Le Blanc K; Rocha V; Gluckman E; Reiffers J; Arcese W; Vossen JM; Jouet JP; Cordonnier C; Frassoni F
J Clin Oncol; 2004 Feb; 22(3):416-23. PubMed ID: 14691124
[TBL] [Abstract][Full Text] [Related]
38. Thrombotic microangiopathy following allogeneic bone marrow transplantation is associated with intensive graft-versus-host disease prophylaxis.
Paquette RL; Tran L; Landaw EM
Bone Marrow Transplant; 1998 Aug; 22(4):351-7. PubMed ID: 9722070
[TBL] [Abstract][Full Text] [Related]
39. Unique risk factors for bacteraemia in allogeneic bone marrow transplant recipients before and after engraftment.
Yuen KY; Woo PC; Hui CH; Luk WK; Chen FE; Lie AK; Liang R
Bone Marrow Transplant; 1998 Jun; 21(11):1137-43. PubMed ID: 9645577
[TBL] [Abstract][Full Text] [Related]
40. Gastroparesis following bone marrow transplantation.
Eagle DA; Gian V; Lauwers GY; Manivel JC; Moreb JS; Mastin S; Wingard JR
Bone Marrow Transplant; 2001 Jul; 28(1):59-62. PubMed ID: 11498745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
